Technical Analysis for MRKR - Marker Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | -9.63% | |
| NR7 | Range Contraction | -9.63% | |
| Doji - Bullish? | Reversal | -9.63% | |
| Wide Bands | Range Expansion | -9.63% | |
| Down 3 Days in a Row | Weakness | -9.63% |
| Alert | Time |
|---|---|
| Down 10% | about 18 hours ago |
| Down 1 ATR | about 18 hours ago |
| Down 5% | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 23 hours ago |
| 200 DMA Resistance | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
Marker Therapeutics, Inc. Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Immunotherapy Treatment Of Cancer Cancer Treatment Oncology Tumor Cancer Immunotherapy Cell Therapy Immunotherapies Virotherapy Ovarian Cancer Hematological Malignancies T Cell Her2 Her2/Neu Breast And Ovarian Cancer Tumor Cell Metastatic Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.1568 |
| 52 Week Low | 2.4377 |
| Average Volume | 36,063 |
| 200-Day Moving Average | 4.05 |
| 50-Day Moving Average | 3.22 |
| 20-Day Moving Average | 3.57 |
| 10-Day Moving Average | 4.13 |
| Average True Range | 0.45 |
| RSI (14) | 51.22 |
| ADX | 39.36 |
| +DI | 23.49 |
| -DI | 16.69 |
| Chandelier Exit (Long, 3 ATRs) | 3.68 |
| Chandelier Exit (Short, 3 ATRs) | 3.78 |
| Upper Bollinger Bands | 4.87 |
| Lower Bollinger Band | 2.27 |
| Percent B (%b) | 0.53 |
| BandWidth | 72.87 |
| MACD Line | 0.28 |
| MACD Signal Line | 0.27 |
| MACD Histogram | 0.011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.43 | ||||
| Resistance 3 (R3) | 4.49 | 4.30 | 4.30 | ||
| Resistance 2 (R2) | 4.30 | 4.11 | 4.27 | 4.25 | |
| Resistance 1 (R1) | 3.98 | 3.98 | 3.89 | 3.92 | 4.21 |
| Pivot Point | 3.79 | 3.79 | 3.74 | 3.76 | 3.79 |
| Support 1 (S1) | 3.47 | 3.60 | 3.38 | 3.41 | 3.11 |
| Support 2 (S2) | 3.28 | 3.47 | 3.25 | 3.07 | |
| Support 3 (S3) | 2.96 | 3.28 | 3.02 | ||
| Support 4 (S4) | 2.90 |
